BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (SEPTEMBER - OCTOBER 2016)

The Liposomal Antiinfluenzal Vaccine

N. N. Ivanova & A. Ju. Volunsky

Introduction: The liposomal antiinfluenzal vaccine was developed with the objective of overcoming the major drawbacks of the currently used influenza vaccines: their relatively low efficacy and the need for annual immunization. Developed the experimental liposomal vaccine consists of the original composition of liposomes containing the viral surface proteins hemagglutinin (HA) and neuraminidase (NA).
The introduction of the experimental liposomal antiinfluenzal vaccine caused the appearance of specific antibodies in 3 times higher after the first immunization and 2 times higher after the second immunization in comparison with antipandemic split vaccine Panenza. Panenza consists of 5 albuminous components, our experimental vaccine contains only 2 albuminous components that reduces risk of the allergic phenomena.

  

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.